This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Zydelig
  • /
  • Dose Optimization Study of Idelalisib in Follicula...
Clinical trial

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Read time: 2 mins
Last updated:14th Jan 2016
Identifier: NCT02536300
This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.
Category Value
Date last updated at source 2017-05-09
Study type(s) Interventional
Expected enrolment 240
Study start date 2016-01-14
Estimated primary completion date 2021-08-01

View full details